Literature DB >> 10453774

Evaluation and rehabilitation of patients with adult motor neuron disease.

K Francis1, J R Bach, J A DeLisa.   

Abstract

Adult motor neuron disease (amyotrophic lateral sclerosis [ALS]) is a neurodegenerative disorder characterized by loss of motor neurons in the cortex, brain stem, and spinal cord, manifested by upper and lower motor neuron signs and symptoms affecting bulbar, limb, and respiratory musculature. Clinically, the disease course is characterized by progressive weakness, atrophy, spasticity, dysarthria, dysphagia, and respiratory compromise, ultimately resulting in death or mechanical ventilation in the vast majority of patients. Patterns of presentation and pathological features of the disease, along with clinical and electrophysiologic criteria for diagnosis, are discussed in this review. Since 8% to 22% of patients survive more than 10 years without ventilator use, meticulous medical and rehabilitation management is extremely important to ensure optimal health and quality of life in these patients. Major issues in the care of individuals with ALS include weakness and spasticity, impairments in activities of daily living and mobility, communication deficits and dysphagia in those with bulbar involvement, respiratory compromise, fatigue and sleep disorders, pain, and psychosocial distress. Research in ALS changes rapidly, but is currently focused on potential etiologic factors such as glutamate excitotoxicity, role of oxidative stress, autoimmunity to calcium channels, and cytoskeletal abnormalities, as well as related treatment initiatives including glutamate modulators, neurotrophic factors, antioxidants, antiapoptotic factors, and gene therapy. Recently, mutations in the gene encoding Cu/Zn superoxide dismutase were identified in a subset of familial ALS patients. Riluzole, a glutamate antagonist and Na-channel blocker, became the only drug currently approved for treatment of ALS after studies showed a small positive effect on survival. Until a definitive treatment or cure for ALS is found, the multifaceted rehabilitation team approach remains the best hope for improving health and survival in this devastating illness.

Entities:  

Mesh:

Year:  1999        PMID: 10453774     DOI: 10.1016/s0003-9993(99)90089-8

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  15 in total

1.  Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Authors:  Radhia Benmohamed; Anthony C Arvanites; Jinho Kim; Robert J Ferrante; Richard B Silverman; Richard I Morimoto; Donald R Kirsch
Journal:  Amyotroph Lateral Scler       Date:  2010-11-12

Review 2.  Diagnostic investigation and multidisciplinary management in motor neuron disease.

Authors:  J A Rocha; C Reis; F Simões; J Fonseca; J Mendes Ribeiro
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

3.  Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties.

Authors:  Guoyao Xia; Radhia Benmohamed; Richard I Morimoto; Donald R Kirsch; Richard B Silverman
Journal:  Bioorg Med Chem Lett       Date:  2014-09-15       Impact factor: 2.823

Review 4.  The impact of rehabilitative interventions on quality of life: a qualitative evidence synthesis of personal experiences of individuals with amyotrophic lateral sclerosis.

Authors:  Ammarah Y Soofi; Vanina Dal Bello-Haas; Michelle E Kho; Lori Letts
Journal:  Qual Life Res       Date:  2017-12-04       Impact factor: 4.147

5.  Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis.

Authors:  Guoyao Xia; Radhia Benmohamed; Jinho Kim; Anthony C Arvanites; Richard I Morimoto; Robert J Ferrante; Donald R Kirsch; Richard B Silverman
Journal:  J Med Chem       Date:  2011-03-04       Impact factor: 7.446

6.  Amyotrophic lateral sclerosis patients' self-reported satisfaction with assistive technology.

Authors:  Kirsten L Gruis; Patricia A Wren; Jane E Huggins
Journal:  Muscle Nerve       Date:  2011-04-01       Impact factor: 3.217

7.  [Amyotrophic lateral sclerosis: management of bulbar symptoms].

Authors:  P Kraft; M Beck; A Grimm; C Wessig; K Reiners; K V Toyka
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

8.  Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis.

Authors:  Thomas S Guillot; Seneshaw A Asress; Jason R Richardson; Jonathan D Glass; Gary W Miller
Journal:  J Mot Behav       Date:  2008-11       Impact factor: 1.328

Review 9.  Management of amyotrophic lateral sclerosis.

Authors:  Philippe Corcia; Vincent Meininger
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Effect of fluoxetine on disease progression in a mouse model of ALS.

Authors:  J E Koschnitzky; K A Quinlan; T J Lukas; E Kajtaz; E J Kocevar; W F Mayers; T Siddique; C J Heckman
Journal:  J Neurophysiol       Date:  2014-03-05       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.